Scott Greenfeder is currently VP Head of Oncology Regulatory Strategy Group 2 for Bayer Pharmaceuticals. Scott has more than 25 years of pharmaceutical industry experience extending from early pre-clinical drug discovery, target identification/validation to regulatory strategy for early, late stage and post-approval clinical development programs. His expertise spans various disease states including respiratory, cardiovascular/metabolic, immunology, pain and oncology. Scott attended Rutgers University for undergraduate studies and has a PhD in molecular biology from the Graduate School of Biological Sciences of New Jersey.